Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid Biosciences Inc. of $90 million of common stock.

Solid Biosciences Inc. is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, Solid Bioscience Inc.’s mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with its lead gene therapy candidate, SGT-001.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate David D. Kim. All members of the Davis Polk team are based in the New York office.

Copy link to share post